Reference is made to the annual general meeting of Targovax ASA (the “Company”) on 30 April 2019 (the “AGM”) where election of members to the board of directors was according to the nomination committee’s proposal. At the same AGM of the Company the board of directors was authorized to extend the Company’s restricted stock unit (“RSU”) program and to issue RSUs to the board members. The RSUs are non-transferable and each RSU gives the right and obligation to acquire one share in the Company at a price of NOK 0.10 per share (corresponding to the nominal value of the shares) subject to satisfaction of the applicable vesting conditions.
If the board members choose to receive the board remuneration in RSUs they must elect to either (i) receive 100% of the compensation in RSUs, (ii) receive 1/3 of the compensation in cash and 2/3 in RSUs, or (iii) receive 2/3 of the compensation in cash and 1/3 in RSUs. The number of RSUs is calculated on the basis of a board remuneration of NOK 500 000 to the chairperson of the board and NOK 290,000 to the other board members, divided by the market price of the Company’s shares calculated as the average share price for the 10 trading days prior to the AGM being NOK 6.34 per share.
Robert Burns has resolved to receive his full board remuneration, as determined by the Company’s annual general meeting in 2019, in the form of RSUs and the board of directors has resolved to issue 45,747 RSUs to Robert Burns. Robert Burns holds 73,946 RSUs, 21,235 options and 64,928 shares in the Company.
Eva-Lotta Allan has resolved to receive 1/3 of the board remuneration, as determined by the Company’s annual general meeting in 2019, in the form of RSUs and the board of directors has resolved to issue 15,249 RSUs to Eva-Lotta Allan. Eva-Lotta Allan holds 66,617 RSUs, no options and no shares in the Company.
Diane Mellett has resolved to receive 1/3 of the board remuneration, as determined by the Company’s annual general meeting in 2019, in the form of RSUs and the board of directors has resolved to issue 15,249 RSUs to Diane Mellett. Diane Mellett holds 65,447 RSUs, no options and no shares in the Company.
Bente-Lill Romøren has resolved to receive 1/3 of the board remuneration, as determined by the Company’s annual general meeting in 2019, in the form of RSUs and the board of directors has resolved to issue 15,249 RSUs to Bente-Lill Romøren. Bente-Lill Romøren holds 35,577 RSUs, no options and no shares in the Company.
Patrick Vink has resolved to receive his full board remuneration, as determined by the Company’s annual general meeting in 2019, in the form of RSUs and the board of directors has resolved to issue 78,873 RSUs to Patrick Vink. Patrick Vink holds 123,159 RSUs, no options and no shares in the Company.
##
For further information please contact:
Torbjørn Furuseth, CFO
Phone: +47 932 11 101
Email: torbjorn.furuseth@targovax.com
About Targovax
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.
Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It activates the immune system to generate tumor-specific immune responses. In a phase I monotherapy trial, ONCOS-102 induced both local and systemic innate and adaptive immune activation, with associated clinical benefit. In an ongoing phase I trial, patients who have progressed on anti-PD1 checkpoint inhibitors and treated with ONCOS-102 in combination with Keytruda, demonstrated responses in three of nine patients (33% ORR) including one complete response. ONCOS-102’s lead indication is mesothelioma, where the virus is currently being tested in a randomized phase I/II trial expected to report around new year 2019-20.